Management of Fluoroquinolone-Induced Urticaria

Introduction to Urticaria Management

The British Journal of Dermatology recommends adding loratadine 10 mg once daily or fexofenadine as a non-sedating antihistamine alongside Benadryl for urticaria management 1, 2

The British Journal of Dermatology suggests loratadine 10 mg once daily as a first-line option, which is completely non-sedating at all doses and can be increased up to 40 mg daily if needed for better control 1, 2, 5
Fexofenadine 180 mg once daily is also a completely non-sedating option 2, 5
Desloratadine 5 mg once daily is another option with the longest half-life (27 hours) 1, 2, 5
The British Journal of Dermatology advises against using cetirizine as a non-sedating option due to its potential to cause sedation in 13.7% of patients 1, 6, 2

The British Journal of Dermatology recommends starting with standard dosing and assessing response after 2-4 weeks 2, 5
If inadequate control, the dose of the non-sedating antihistamine can be increased up to 4-fold (e.g., loratadine up to 40 mg daily) before adding other therapies 1, 2, 5

The British Journal of Dermatology suggests adding an H2 antihistamine (famotidine 20 mg) for better urticaria control 1, 7, 8
Topical symptomatic relief can be achieved with cooling antipruritic lotions such as 1% menthol in aqueous cream 1, 9, 2, 10

The British Journal of Dermatology advises against assuming Benadryl alone is sufficient, as first-generation antihistamines can cause reduced concentration and performance 1, 7, 8
Combining multiple first-generation antihistamines should be avoided due to prolonged daytime drowsiness 2
NSAIDs and aspirin should be avoided as they can worsen urticaria through cyclooxygenase inhibition 9, 2, 10

The Clinical Microbiology and Infection journal recommends monitoring closely during the first dose and throughout treatment in a controlled clinical setting 3, 4
Emergency medications, including epinephrine, should be immediately available due to the risk of anaphylaxis 3, 4, 11